SARS-CoV-2 ORF7a anticorps
Aperçu rapide pour SARS-CoV-2 ORF7a anticorps (ABIN7272994)
Antigène
Reactivité
Hôte
Clonalité
Conjugué
Application
-
-
Fonction
- anti-ORF7a (SARS-CoV-2)
-
Séquence
- MYHYQECVRG TTVLLKEPCS SGTYEGNSPF HPLADNKFAL TCFSTQFAFA CPDGVKHVYQ LRARSVSPKL FIRQEEVQE
-
Specificité
- In lysates of transfected cells with the plasmid containing the sequence used, detects the fusion protein by Western blot.
-
Réactivité croisée (Details)
- Reacts with SARS-CoV-2 protein
-
Purification
- Epitope affinity purified
-
Immunogène
- Affinity purified recombinant fusion protein ORF7a (residues 18 to 95) produced in E. coli.
-
Isotype
- IgG
-
-
-
-
Indications d'application
- WB:1:500-1:2,000
-
Restrictions
- For Research Use only
-
-
-
Concentration
- 3 mg/mL
-
Buffer
- PBS, 20 % glycerol and 0.05 % sodium azide.
-
Agent conservateur
- Sodium azide
-
Précaution d'utilisation
- This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.
-
Conseil sur la manipulation
- The antibody solution should be gently mixed before use.
-
Stock
- 4 °C,-20 °C
-
Stockage commentaire
- For continuous use, store at 2-8 C for one-two days. For extended storage, store in -20 C freezer. Working dilution samples should be discarded if not used within 12 hours.
-
-
- SARS-CoV-2 ORF7a
-
Autre désignation
- ORF7a (SARS-CoV-2)
-
Classe de substances
- Viral Protein
-
Sujet
-
ORF7a is a SARS-CoV accessory protein that is composed of a type I transmembrane protein that localizes primarily to the Golgi apparatus and also be found on the cell surface. This protein has been implicated on several mechanisms such as suppressing both transgene and virus-induced gene silencing by reducing the levels of small interfering RNA (siRNA), attachment and modulation of leukocytes by biding to host ITGAL and playing a role as antagonist of host tetherin (BST2) by disrupting its antiviral effect.
ORF7a SARS Coronavirus-2 antibody.
Antigène
-